Speaking from the heart: see one man’s journey to not let HS get him down
Despite affecting millions worldwide, many have not heard of hidradenitis suppurativa, or HS. Learn more about the condition through one person’s journey.
AbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease

NORTH CHICAGO, Ill., Nov. 14, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA® (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy. If approved, HUMIRA will become the first and only biologic treatment option for patients 12 years of age and older. HUMIRA was approved for adults with moderate to severe HS by the European Commission in July 2015. 

AbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy of Dermatology and Venereology Congress

NORTH CHICAGO, Ill., Sept. 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that new data on HUMIRA® (adalimumab) and investigational medicine risankizumab (formerly BI 655066), an IL-23 inhibitor, will be presented at the 25th European Academy of Dermatology and Venereology Congress (EADV), September 28 - October 2, in Vienna, Austria. These presentations build upon AbbVie's continued scientific leadership in serious dermatological conditions including psoriasis, psoriatic arthritis and hidradenitis suppurativa.

World-Renowned Soccer Player Brandi Chastain Partners with AbbVie to Raise Awareness about Inflammatory Bowel Disease and Share Personal Story

NORTH CHICAGO, Ill., July 19, 2016 /PRNewswire/ -- World-renowned soccer player Brandi Chastain today announced her partnership with AbbVie, a global biopharmaceutical company, on the new educational program, My IBD Game Plan. The program is designed to help individuals living with Crohn's disease and ulcerative colitis, the two most common forms of inflammatory bowel disease (IBD), create a plan to help manage everyday life with these diseases. Inflammatory bowel disease affects as many as 1.6 million Americans.1 The resources on the program website, www.IBDGamePlan.com, will help people living with IBD and their caregivers proactively work with their healthcare providers and support team to take control and manage the symptoms of these diseases.

How to overcome the blood-brain barrier to deliver new medicines

The brain’s protection barrier prevents medicines from getting in, but new approaches are finding ways to bust through and treat central nervous system diseases.

From friend to foe: when your immune system turns against you and how to turn it back

The immune system can go haywire in autoimmune diseases and cancer. While this may affect the body in different ways, the key to treating these diseases is interconnected. 

AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA® (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress

PARIS, July 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today will present findings of a Phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients treated with HUMIRA® (adalimumab) achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis compared to patients receiving placebo. The study will be presented at Psoriasis 2016 - 5th Congress of the Psoriasis International Network taking place July 7 - 9 in Paris, alongside additional abstracts.

AbbVie's HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis

NORTH CHICAGO, Ill., June 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis. HUMIRA is now the first and only FDA-approved non-corticosteroid therapy available for adults with non?infectious intermediate, posterior and panuveitis. This approval marks the 10th approved indication for HUMIRA in the United States for immune-mediated diseases.

AbbVie Scholarship Programs Recognize Exceptional Students Living with Chronic Inflammatory Diseases

NORTH CHICAGO, Ill., June 16, 2016 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced the recipients of the AbbVie Crohn's & Colitis Scholarship and the AbbVie Rheumatology Scholarship. These scholarships provide financial support for exceptional students living with inflammatory bowel disease, including Crohn's disease or ulcerative colitis; rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis, as they pursue higher education goals.

AbbVie's Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016)

NORTH CHICAGO, Ill., June 2, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and research, including real-world evidence, aiming to improve clinical outcomes for patients with rheumatologic diseases, will be presented at the Annual European Congress of Rheumatology (EULAR 2016), June 8 – 11, in London. These data add to the body of evidence supporting the safety and efficacy of adalimumab, an anti-TNF therapy, and AbbVie's continued commitment to innovation across immunology.